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1. INTRODUCTION {#jcb26445-sec-0002}
===============

Prostate cancer (PC) is the leading male cancer worldwide. In 2016, PC is estimated to be responsible for 26 120 deaths in the United States.[1](#jcb26445-bib-0001){ref-type="ref"} Early PC is localized which can be curable by a variety of therapies: chemotherapy, radiation therapy, radical prostatectomy, and cryotherapy, etc. Unfortunately, approximately 23‐40% of these patients would go on to develop metastatic tumors after initial therapy.[2](#jcb26445-bib-0002){ref-type="ref"} Prostate tumors often metastasize to bone and other organs to cause patients death.[3](#jcb26445-bib-0003){ref-type="ref"} At present, metastatic cases are treated with androgen‐deprivation therapy to induce apoptosis of tumor cells or to inhibit cells growth. This will further induce PC to be insensitive to hormone and progress to CRPC, which is essentially untreatable.

In spite of the prevalence of PC, there are no diagnostic or prognostic biomarkers to specifically and precisely distinguish its aggressiveness. In the early 1990s, the detection of PC dramatically increased due to the introduction of the prostate‐specific antigen (PSA) test, which had been used as a routine assay in clinic. PSA levels are not specific for PC, and may fluctuate to induce false‐positive due to infections, inflammation, or hyperplasia, etc. Due to the poor correlation between PSA levels and PC which leads to overdiagnosis and overtreatment,[4](#jcb26445-bib-0004){ref-type="ref"}, [5](#jcb26445-bib-0005){ref-type="ref"} the US Preventive Services Task Force recommends physicians not to routinely perform PSA‐based screening.[6](#jcb26445-bib-0006){ref-type="ref"}, [7](#jcb26445-bib-0007){ref-type="ref"}, [8](#jcb26445-bib-0008){ref-type="ref"} Moreover, the prostate needle biopsy has also obvious defects because only 2% of the prostate tumor samples can be sampled by puncture.[9](#jcb26445-bib-0009){ref-type="ref"} Therefore, we still need to seek unique biomarkers discriminating different stages of PC.

miRNAs are small, single‐stranded, non‐coding, 21‐23 nucleotides RNAs that are conserved and endogenous, and have been shown to regulate the expression of approximately 60% of human genes.[10](#jcb26445-bib-0010){ref-type="ref"} miRNAs post‐transcriptionally regulate gene expression via base‐pairing with 3′‐untranslated regions (UTRs) of mRNA, and are found to be located in fragile regions involved in various cancers.[11](#jcb26445-bib-0011){ref-type="ref"} miRNAs may regulate a wide range of biological processes: proliferation, apoptosis, development, and differentiation, etc, and are discovered to be aberrantly expressed in various carcinomas. Thus, more and more researchers are willing to consider miRNAs as diagnostic or prognostic biomarkers. Recently, miRNAs have attracted the attention of urologists and oncologists, because of their potential uses for the urologic cancers diagnosis, monitoring, and treatment. Specific miRNA may be used as marker to detect PC, predict prognosis, and monitor therapy. miRNAs are attractive biomarkers because they can be easily extracted from a wide range of biologic samples, and are stable in various storage conditions. Furthermore, miRNAs can be accurately detected by a variety of techniques, for example, qRT‐PCR, microarray, and next‐generation sequencing, etc. However, there are some controversies on miRNAs as biomarkers, because some studies obtain statistically insignificant results, and some draw inconsistent conclusions. In view of these results from different patient cohorts or various detection methods or different data analysis platforms, miRNAs are still considered an attractive biomarkers to assess recurrence and therapeutic effect. Therefore, we conducted a meta‐analysis to clarify the role of miRNAs for tumor progression and RFS and OS in PC clinical specimens.

2. MATERIALS AND METHODS {#jcb26445-sec-0003}
========================

2.1. Search strategy {#jcb26445-sec-0004}
--------------------

We performed a detailed literature search in PubMed, Embase, Cochrane, and Chinese National Knowledge Infrastructure databases to obtain relevant articles for this meta‐analysis. Relevant studies were selected according to a combination of keywords and Medical Subject Headings (MeSH): ("prostate cancer" or "prostate neoplasm" or "prostate tumor") and ("microRNAs" or "miRNAs" or "miR‐") and ("marker or "biomarker"). All selected studies in English or Chinese were viewed, and their reference lists were also examined for other eligible publications. Most studies were published between 2007and 2017. The last search update was finished on July 8, 2017. These studies regarding miRNAs and PC are performed in clinical samples or PC cell lines. Published data are subject to the limitation of small sample size and selection bias.

2.2. Inclusion and exclusion criteria {#jcb26445-sec-0005}
-------------------------------------

More than 1300 articles were retrieved, and 104 publications were included and reviewed in the meta‐analysis (Figure [1](#jcb26445-fig-0001){ref-type="fig"}). Eligible studies had to fit the following inclusion criteria: (i) a kind of miRNA was involved in the studies; (ii) patients with PC were studied, and gold standard test (eg, histological examination) was used for the PC diagnosis; (iii) prostate tissue or serum or urine samples were used from PC patients or non‐PC patients for miRNA expression comparison; and (iv) validation method and enough patients\' information were reported. Eligible studies that met above mentioned criteria were further evaluated and excluded according to a selection process showed in Figure [1](#jcb26445-fig-0001){ref-type="fig"}. Exclusion criteria were as follows: (i) reviews, letters, commentary, or erratum; (ii) non‐English or non‐Chinese studies; (iii) data was obtained from PC cell lines; (iv) no sufficient data to extract; and (v) duplicate records.

![Flowchart of study selection process in this meta‐analysis](JCB-119-2763-g002){#jcb26445-fig-0001}

2.3. Data extraction {#jcb26445-sec-0006}
--------------------

We assessed the data quality of each publication and extracted the following information: (i) basic features, such as first author, publication year, case region, study design, sample number, validation method, and detected miRNAs, as showed in Table [1](#jcb26445-tbl-0001){ref-type="table-wrap"}; (ii) expression levels or fold‐change of detected miRNAs and predictive data, including OS and RFS; and (iii) information needed for quality assessment. If there were no data that could be extracted directly, we used the computer of revman 5.3 software to calculate and generate the relevant data.

###### 

The main characteristics of included studies

  First author & publishing year   Region              Study design   Detected samples                                                                                                                                                                                                                                       Validation                             miRNA                                                                                                  Refs.
  -------------------------------- ------------------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------
  Robert S. Hudson 2012            USA                 PR             A large publicly available data set consisting of 99 primary tumors and 14 distant metastasis and patient data for disease recurrence                                                                                                                  qRT‐PCR                                miR‐1                                                                                                  [32](#jcb26445-bib-0032){ref-type="ref"}
  Yun‐Li Chang 2015                China               P              20 paired of PC tumors and adjacent normal tissues                                                                                                                                                                                                     qRT‐PCR                                miR‐7                                                                                                  [33](#jcb26445-bib-0033){ref-type="ref"}
  Annika Fendler 2011              Canada Germany      P              52 primary prostate cancers and normal adjacent tissues                                                                                                                                                                                                qRT‐PCR                                miR‐10b                                                                                                [34](#jcb26445-bib-0034){ref-type="ref"}
  Bing Yang 2016                   China               P              92 PC 85 BPH 97 controls                                                                                                                                                                                                                               qRT‐PCR                                miR‐21                                                                                                 [16](#jcb26445-bib-0016){ref-type="ref"}
  Christian Melbø‐Jørgensen 2014   Norway              P              535 PC patients 30 patients (14 patients with rapid biochemical failure (BF) and 16 patients without BF) with Gleason score 7                                                                                                                          microarray qRT‐PCR ISH                 miR‐21                                                                                                 [35](#jcb26445-bib-0035){ref-type="ref"}
  Ernest K Amankwah 2013           USA                 P              28 recurrent and 37 non‐recurrent prostate cancer cases                                                                                                                                                                                                qRT‐PCR                                miR‐21                                                                                                 [28](#jcb26445-bib-0028){ref-type="ref"}
  Judit Ribas 2009                 USA                 P              10 pairs                                                                                                                                                                                                                                               Northern blot                          miR‐21                                                                                                 [36](#jcb26445-bib-0036){ref-type="ref"}
  Marco Folini 2010                Italy               P              36 pairs of PC and N tissues                                                                                                                                                                                                                           qRT‐PCR                                miR‐21                                                                                                 [37](#jcb26445-bib-0037){ref-type="ref"}
  Sabrina Thalita Reis 2012        Brazil              P              53 PC 11 benign prostatic hyperplasia (BPH)                                                                                                                                                                                                            qRT‐PCR                                miR‐21                                                                                                 [38](#jcb26445-bib-0038){ref-type="ref"}
  Sarvesh Jajoo 2013               USA                 P              18 PC                                                                                                                                                                                                                                                  qRT‐PCR                                miR‐21                                                                                                 [39](#jcb26445-bib-0039){ref-type="ref"}
  Tao Li 2012                      China               P              169 radical prostatectomy tissue samples                                                                                                                                                                                                               ISH microarray                         miR‐21                                                                                                 [40](#jcb26445-bib-0040){ref-type="ref"}
  Wei Huang 2015                   China               P              75 localized PC 75 healthy volunteers                                                                                                                                                                                                                  qRT‐PCR                                miR‐21                                                                                                 [17](#jcb26445-bib-0017){ref-type="ref"}
  Yangbo Guan 2016                 China               P              85 PC patients and 40 adjacent noncancerous biospy specimens                                                                                                                                                                                           qRT‐PCR ISH                            miR‐21                                                                                                 [19](#jcb26445-bib-0019){ref-type="ref"}
  Songwang Cai 2015                China               P              3 pairs of primary human prostate cancer and adjacent non‐tumor tissues 20 pairs of human prostate cancer and adjacent non‐tumor tissues. 123 prostate cancer tissues                                                                                  Sequencing qRT‐PCR                     miR‐23a                                                                                                [41](#jcb26445-bib-0041){ref-type="ref"}
  Hui‐chan He 2012                 China               P              4 pairs 20 pairs 26 PC 20N                                                                                                                                                                                                                             microarray qRT‐PCR ISH                 miR‐23b                                                                                                [42](#jcb26445-bib-0042){ref-type="ref"}
  Shahana Majid 2012               USA                 P              118 pairs of laser captured microdisected tissue samples an unmatched group of 27 benign prostatic hyperplasia (BPH) and 20 tumor samples another cohort of 48 samples                                                                                 qRT‐PCR qMSP ISH                       miR‐23b                                                                                                [43](#jcb26445-bib-0043){ref-type="ref"}
  Yusuke Goto 2014                 Japan               P              41 noncancerous tissues 49 PC tissues                                                                                                                                                                                                                  qRT‐PCR                                miR‐23b/27b/24‐1                                                                                       [44](#jcb26445-bib-0044){ref-type="ref"}
  Kai Guo 2016                     China               P              140 pairs of fresh PC tissues and normal control tissues                                                                                                                                                                                               qRT‐PCR                                miR‐26a‐5p                                                                                             [45](#jcb26445-bib-0045){ref-type="ref"}
  Xiao‐hui Ling 2014               China               P              103 pairs of prostate tumor tissues and adjacent benign tissues and 28 benign prostate tissues gene expression omnibus (GEO) repository database (<http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE34932).                                      qRT‐PCR                                miR‐30c                                                                                                [46](#jcb26445-bib-0046){ref-type="ref"}
  Xiao‐Hui Ling 2016               China               P              98 tumor tissue 20 benign prostate hyperplasia (BPH) specimens                                                                                                                                                                                         qRT‐PCR                                miR‐30c                                                                                                [47](#jcb26445-bib-0047){ref-type="ref"}
  Naohito Kobayashi 2012           Japan               P              56 pairs of primary PC and controls                                                                                                                                                                                                                    Oligo chips qRT‐PCR                    miR‐30d                                                                                                [48](#jcb26445-bib-0048){ref-type="ref"}
  SE Jalava 2012                   Finland             P              5 benign prostatic hyperplasia (BPH) and 28 primary PCs 7 BPH and 14 CRPCs                                                                                                                                                                             microarray                             miR‐32                                                                                                 [49](#jcb26445-bib-0049){ref-type="ref"}
  Q. Li 2017                       China               P              paired prostate cancer tissue and adjacent normal tissue                                                                                                                                                                                               qRT‐PCR                                miR‐33a                                                                                                [50](#jcb26445-bib-0050){ref-type="ref"}
  Shahana Majid 2013               USA                 P              148 matched human tissue samples an unmatched group of 27 benign prostatic hyperplasia (BPH) and 20 tumor samples                                                                                                                                      qRT‐PCR ISH                            miR‐34b                                                                                                [51](#jcb26445-bib-0051){ref-type="ref"}
  Zandra Hagman 2010               Sweden              P              49 PC patients and 25 benign prostatic hyperplasia                                                                                                                                                                                                     qRT‐PCR                                miR‐34c                                                                                                [52](#jcb26445-bib-0052){ref-type="ref"}
  Robert S. Hudson 2013            USA                 PR             dataset for 28 non‐cancerous tissues, 99 primary tumors and 14 distant metastases with patient data for disease recurrence.                                                                                                                            qRT‐PCR                                miR‐106b‐25                                                                                            [53](#jcb26445-bib-0053){ref-type="ref"}
  Xu‐Bao Shi 2013                  USA                 P              19 BPHs, 44 primary CaPs, 6 lymph node metastases, and 10 CR tumors                                                                                                                                                                                    qRT‐PCR                                miR‐124                                                                                                [54](#jcb26445-bib-0054){ref-type="ref"}
  Xiaoke Sun 2013                  China               P              A series of 128 cases with PCa                                                                                                                                                                                                                         qRT‐PCR                                miR‐126                                                                                                [55](#jcb26445-bib-0055){ref-type="ref"}
  Xiaoke Sun 2015                  China               P              128 PC tissue and serum and matched controls                                                                                                                                                                                                           qRT‐PCR                                miR‐128                                                                                                [56](#jcb26445-bib-0056){ref-type="ref"}
  Song Xu 2015                     China               P              98 PC and 56 health controls                                                                                                                                                                                                                           qRT‐PCR                                miR‐129                                                                                                [57](#jcb26445-bib-0057){ref-type="ref"}
  Song Xu 2016                     China               P              118 pairs of PC and noncancerous tissue                                                                                                                                                                                                                qRT‐PCR                                miR‐129                                                                                                [58](#jcb26445-bib-0058){ref-type="ref"}
  Xia Li 2014                      China               P              135 specimens of patients with prostate cancer, 18 patients with prostatic intraepithelial neoplasia (PIN), and 25 normal prostate tissue samples)                                                                                                     qRT‐PCR ISH                            miR‐133b                                                                                               [59](#jcb26445-bib-0059){ref-type="ref"}
  Cheng Pang 2016                  China               P              45 PC patients, 45 benign prostatic hyperplasia (BPH) patients and 50 healthy controls serum peripheral whole blood samples                                                                                                                            qRT‐PCR                                miR‐139‐5p                                                                                             [24](#jcb26445-bib-0024){ref-type="ref"}
  Jason C. Gonzales 2011           USA                 P              21 PC                                                                                                                                                                                                                                                  qRT‐PCR                                miR‐141                                                                                                [60](#jcb26445-bib-0060){ref-type="ref"}
  Zhuo Li 2015                     China               P              20 PCa, 20 BPH, and 20 control volunteers 51 PC and 40 control volunteers                                                                                                                                                                              qRT‐PCR                                miR‐141                                                                                                [61](#jcb26445-bib-0061){ref-type="ref"}
  M Avgeris 2013                   Greece              P              73 radical prostatectomy‐treated PC patients and 64 benign prostate hyperplasia (BPH) patients                                                                                                                                                         qRT‐PCR                                miR‐145                                                                                                [62](#jcb26445-bib-0062){ref-type="ref"}
  Bin Xu 2015                      China               PR             13 ADPC 9 AIPC MSKCC prostate cancer database (GSE21032)                                                                                                                                                                                               microarray qRT‐PCR                     miR‐146a‐5p                                                                                            [25](#jcb26445-bib-0025){ref-type="ref"}
  Liu Dezhong 2015                 China               P              167 PC 4 pairs of PC and adjacent to tumor healthy tissues to tumor                                                                                                                                                                                    qRT‐PCR                                miR‐150                                                                                                [63](#jcb26445-bib-0063){ref-type="ref"}
  Shaniece C. Theodore 2014        USA UK              P              39 pairs of prostate cancer tissues and controls (20 AA and 19 CA) 97 primary tumors and 13 metastases                                                                                                                                                 qRT‐PCR                                miR‐152                                                                                                [64](#jcb26445-bib-0064){ref-type="ref"}
  Zsuzsanna Lichner 2013           Canada Germany      P              41 prostatectomy samples were dichotomized to 27 high‐risk and 14 low‐risk The validation set: 35 high‐risk patients and 29 low‐risk patients                                                                                                          microarray qRT‐PCR                     miR‐152                                                                                                [65](#jcb26445-bib-0065){ref-type="ref"}
  Ranlu Liu 2013                   China               P              5 PC 3 BPH                                                                                                                                                                                                                                             array                                  miR‐182                                                                                                [66](#jcb26445-bib-0066){ref-type="ref"}
  Katsuki Tsuchiyama 2013          Japan               P              patient set 1: 22 GP 3, 35 GP 4, and 12 GP 5 patient set 2: 10 GP 4 Cancer tissues from each GP and adjacent normal counterparts were separately collected using LCM                                                                                   qRT‐PCR                                miR‐182‐5p                                                                                             [67](#jcb26445-bib-0067){ref-type="ref"}
  Hongtuan Zhang 2015              China               P              180 pairs of PC and adjacent noncancerous tissues                                                                                                                                                                                                      qRT‐PCR                                miR‐188‐5p                                                                                             [68](#jcb26445-bib-0068){ref-type="ref"}
  Amelie Hailer 2014               Germany             P              15 BPH 161 PC 17 LNM                                                                                                                                                                                                                                   qRT‐PCR                                miR‐203                                                                                                [69](#jcb26445-bib-0069){ref-type="ref"}
  Berlinda Verdoodt 2013           Germany             P              111 pairs of formalin‐fixed paraffin‐embedded (FFPE) prostatectomy specimens with primary prostate adenocarcinoma (PCa) and control                                                                                                                    qRT‐PCR                                miR‐205                                                                                                [70](#jcb26445-bib-0070){ref-type="ref"}
  Charis Kalogirou 2013            Germany Belgium     P              105 HRPCa for study collective and 10 BHP 78 HRPCa for validation                                                                                                                                                                                      qRT‐PCR                                miR‐205                                                                                                [71](#jcb26445-bib-0071){ref-type="ref"}
  Sigve Andersen 2016              Norway              P              535 prostatectomy patients                                                                                                                                                                                                                             microarray ISH                         miR‐210                                                                                                [72](#jcb26445-bib-0072){ref-type="ref"}
  Aida Gordanpour 2011             Canada              P              153 radical prostatectomy samples                                                                                                                                                                                                                      microarray qRT‐PCR                     miR‐221                                                                                                [73](#jcb26445-bib-0073){ref-type="ref"}
  Burkhard Kneitz 2014             Germany Belgium     P              cohort 1, *N* = 134; cohort 2, *n* = 89                                                                                                                                                                                                                qRT‐PCR                                miR‐221                                                                                                [74](#jcb26445-bib-0074){ref-type="ref"}
  Yongbao Wei 2014                 China               P              10 pairs of PC tissues and adjacent non‐cancerous tissues                                                                                                                                                                                              qRT‐PCR                                miR‐223‐3p                                                                                             [75](#jcb26445-bib-0075){ref-type="ref"}
  Hao Fu 2015                      China               PR             A 4 and 20 pairs of primary PC and adjacent non‐tumor frozen samples the Taylor dataset (149 primary PC tissues and 29 adjacent non‐cancerous prostate tissues)                                                                                        array qRT‐PCR                          miR‐224                                                                                                [76](#jcb26445-bib-0076){ref-type="ref"}
  Konstantinos Mavridis 2013       Greece              P              66 BPH or 73 CaP                                                                                                                                                                                                                                       qRT‐PCR                                miR‐224                                                                                                [77](#jcb26445-bib-0077){ref-type="ref"}
  Zhuo‐Yuan Lin 2014               China USA           P              4 and 20 pairs of primary PC and adjacent non‐tumor frozen samples Human PC tissue microarrays (TMA) consisting 114 PC tissues respectively from Caucasian and African‐American PC patients                                                            array qRT‐PCR ISH                      miR‐224                                                                                                [78](#jcb26445-bib-0078){ref-type="ref"}
  Jian‐Jun Wei 2011                USA                 P              TMA100 contained 100 PC cases (from the Cooperative PC Tissue Resource at New York University) and TMA96 contained 96 cases (from Northwestern University).                                                                                            microarray qRT‐PCR ISH                 miR‐296                                                                                                [79](#jcb26445-bib-0079){ref-type="ref"}
  Chendil Damodaran 2016           USA                 P              58 FFPE 4 metastatic tumors, 6 fresh tumor tissues and 13 BPH                                                                                                                                                                                          qRT‐PCR                                miR‐301a                                                                                               [80](#jcb26445-bib-0080){ref-type="ref"}
  Robert K. Nam 2016               Canada              P              585 prostate cancer                                                                                                                                                                                                                                    qRT‐PCR                                miR‐301a                                                                                               [81](#jcb26445-bib-0081){ref-type="ref"}
  Si‐wei Xiong 2013                China               P              20 clinical PC tissues 104 clinical PC tissues                                                                                                                                                                                                         qRT‐PCR ISH                            miR‐335                                                                                                [82](#jcb26445-bib-0082){ref-type="ref"}
  Sven Wach 2015                   Germany             P              146 PC patients, 35 benign prostate hyperplasia (BPH) patients and 18 healthy controls serum                                                                                                                                                           qRT‐PCR                                miR‐375                                                                                                [31](#jcb26445-bib-0031){ref-type="ref"}
  Yuan Wang 2016                   USA                 R              495 tumor tissues and 52 normal tissues from TCGA data                                                                                                                                                                                                 qRT‐PCR                                miR‐375                                                                                                [83](#jcb26445-bib-0083){ref-type="ref"}
  N Bucay 2017                     USA                 PR             TCGA(187 primary prostate adenocarcinoma cases) validation cohort: 112 PC FFPE tissues and matched adjacent normals                                                                                                                                    qRT‐PCR                                miR‐383                                                                                                [84](#jcb26445-bib-0084){ref-type="ref"}
  Martin Mørck Mortensen 2014      Denmark             P              36 prostate cancer Samples 163 radical prostatectomy patients 40 patients (20 recurrent and 20 non‐recurrent patients)                                                                                                                                 qRT‐PCR                                miR‐449b                                                                                               [85](#jcb26445-bib-0085){ref-type="ref"}
  Melissa Colden 2017              USA                 PR             48 pairs of LCM tissue samples validation cohort: 56 prostate adenocarcinoma (TCGA database)                                                                                                                                                           qRT‐PCR                                miR‐466                                                                                                [86](#jcb26445-bib-0086){ref-type="ref"}
  X. M. Tian 2017                  China               P              20 prostate cancer tumor tissues 20 tumor‐adjacent tissues and 20 normal prostate tissues                                                                                                                                                              qRT‐PCR                                miR‐509‐5p                                                                                             [87](#jcb26445-bib-0087){ref-type="ref"}
  Jayant K. Rane 2015              UK                  P              5 benign prostatic hyperplasia 5 G7 prostate cancer, and 3 castration‐resistant PC (CRPC)                                                                                                                                                              microarray                             miR‐548c‐3p                                                                                            [88](#jcb26445-bib-0088){ref-type="ref"}
  Takeshi Chiyomaru 2013           USA                 P              48 pairs of PC tissues and adjacent non‐cancerous tissues                                                                                                                                                                                              microarray qRT‐PCR                     miR‐574‐3p                                                                                             [89](#jcb26445-bib-0089){ref-type="ref"}
  Ze‐Hua Zuo 2015                  USA                 P              77 organ donor (OD) prostates, 324 benign prostate tissues adjacent to cancer, and 216 PCs                                                                                                                                                             qRT‐PCR ISH                            miR‐650                                                                                                [90](#jcb26445-bib-0090){ref-type="ref"}
  Li Jiao 2014                     China               P              127 patients with prostate cancer and 10 patients with benign prostatic hyperplasia (BPH)                                                                                                                                                              qRT‐PCR microarray ISH                 miR‐663                                                                                                [91](#jcb26445-bib-0091){ref-type="ref"}
  Sharanjot Saini 2012             USA                 P              40 PC and 8 normal 96 paired                                                                                                                                                                                                                           ISH qRT‐PCR                            miR‐708                                                                                                [92](#jcb26445-bib-0092){ref-type="ref"}
  Dibash K. Das 2016               USA                 P              404 PC (389 CA and 15 AA)                                                                                                                                                                                                                              qRT‐PCR                                miR‐1207‐3p                                                                                            [93](#jcb26445-bib-0093){ref-type="ref"}
  Nathan Bucay 2016                USA                 P              100 pairs of PC and adjacent normals                                                                                                                                                                                                                   qRT‐PCR                                miR‐3622b                                                                                              [94](#jcb26445-bib-0094){ref-type="ref"}
  Yang Wang 2016                   China               P              3 CRPC and 3 ADPC samples 30 ADPC tissues and 18 CRPC tissues                                                                                                                                                                                          microarray qRT‐PCR                     miR‐4638‐5p                                                                                            [95](#jcb26445-bib-0095){ref-type="ref"}
  Albertoivan S. Guadarrama 2016   Mexico              P              73 PC urine and 70 BPH urine                                                                                                                                                                                                                           qRT‐PCR                                miR‐100 miR‐200b                                                                                       [96](#jcb26445-bib-0096){ref-type="ref"}
  Betina Katz 2014                 Brazil              P              51 localized prostate cancer (PCa)                                                                                                                                                                                                                     qRT‐PCR                                miR‐30a miR‐200b                                                                                       [15](#jcb26445-bib-0015){ref-type="ref"}
  Chunjiao Song 2015               China               P              7 G\>7 8 G7 9 Non‐cancerous Samples 7 8 9 12 G\>7 12 G7 12 BPH                                                                                                                                                                                         sequencing qRT‐PCR                     miR‐125b‐5p miR‐126‐5p miR‐151a‐5p miR‐221‐3p miR‐222‐3p miR‐486‐5p                                    [97](#jcb26445-bib-0097){ref-type="ref"}
  Darina Kachakova 2015            Bulgaria            P              59 prostate cancer (PC) patients and two groups of controls: 16 benign prostatic hyperplasia (BPH) samples and 11 young asymptomatic men                                                                                                               qRT‐PCR                                miR‐30c miR‐141 miR‐375 let‐7c                                                                         [98](#jcb26445-bib-0098){ref-type="ref"}
  D Lin 2011                       China               P              35 PC (17 aggressive and 18 non‐aggressive)                                                                                                                                                                                                            qRT‐PCR                                miR‐221 miR‐222                                                                                        [99](#jcb26445-bib-0099){ref-type="ref"}
  Fulya Yaman Agaoglu 2011         Turkey              P              51 PC (26 local/local advanced or 25 metastatic PCa) 20 healthy individuals                                                                                                                                                                            qRT‐PCR                                miR‐21 miR‐141 miR‐221                                                                                 [100](#jcb26445-bib-0100){ref-type="ref"}
  Heather H. Cheng 2013            USA                 P              25 mCRPC and 25 healthy donor serum pools the sera of an additional 21 mCRPC patients and 20 age‐matched healthy Controls for validation                                                                                                               array qRT‐PCR                          miR‐141 miR‐200a/c miR‐210 miR‐375                                                                     [20](#jcb26445-bib-0020){ref-type="ref"}
  Hui‐Ming Lin 2017                Australia           P              Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                                                                                                                qRT‐PCR                                miR‐20a/20b miR‐21 miR‐25 miR‐132 miR‐145a miR‐200a/b/c miR‐222 miR‐301b miR‐375 miR‐429d miR‐590‐5p   [29](#jcb26445-bib-0029){ref-type="ref"}
  Irene Casanova‐Salas 2014        Spain               PR             10 normal prostate and 50 prostate cancer samples an independent cohort of 273 paraffin embedded prostate cancer samples Another 92 urine samples GEO (Gene Expression Omnibus) database Accession No. GSE45604 (<http://www.ncbi.nlm.nih.gov/geo/>)   qRT‐PCR                                miR‐182 miR‐187                                                                                        [101](#jcb26445-bib-0101){ref-type="ref"}
  Ivan D. Osipov 2016              Russia              P              Blood samples from 47 healthy donors and 48 prostate cancer (PC) patients                                                                                                                                                                              qRT‐PCR                                miR‐141 miR‐205                                                                                        [102](#jcb26445-bib-0102){ref-type="ref"}
  Jorge Torres‐Ferreira 2017       Portugal            P              180 localized PC and 15 control 95 urine sediments and 46 controls 74 prostate biopsies                                                                                                                                                                Human Methylation 450 Bead Chip qMSP   miR‐34b/c miR‐129‐2 miR‐152 miR‐193b miR‐663a miR‐1258                                                 [103](#jcb26445-bib-0103){ref-type="ref"}
  Katia R. M. Leite 2011‐1         Brazil              P              18 localized high grade prostate carcinoma (PC) with mean Gleason score 8.6, all staged pT3 4 patients with metastatic, androgen‐independent prostate carcinoma 6 nonneoplastic tissue (benign prostate hyperplasia)                                   qRT‐PCR                                miR‐100 miR‐218 Let‐7c                                                                                 [26](#jcb26445-bib-0026){ref-type="ref"}
  Katia R. M. Leite 2011‐3         Brazil              P              49 prostate cancer (28 men without and 21 with biochemical recurrence)                                                                                                                                                                                 qRT‐PCR                                miR‐100 miR‐145 miR‐191                                                                                [27](#jcb26445-bib-0027){ref-type="ref"}
  Katia R. M. Leite 2013           Brazil              P              63 localized prostate carcinoma 15 high grade prostate intraepithelial neoplasia (HGPIN) 14 localized favorable CaP and 34 unfavorable, mostly non‐organ‐confined disease.                                                                             qRT‐PCR                                miR‐21 miR‐206                                                                                         [22](#jcb26445-bib-0022){ref-type="ref"}
  Kristina Stuopelytė 2016         Lithuania           P              13 PC 143 urine PC and 23 urine BPH 52 PC and 12 N                                                                                                                                                                                                     microarray qRT‐PCR                     miR‐19a/b miR‐21 miR‐95                                                                                [104](#jcb26445-bib-0104){ref-type="ref"}
  Kristina Stuopelyte 2016         Lithuania           P              56 Cancerous and 16 non‐cancerous 215 PC 23 benign prostatic hyperplasia and 62 asymptomatic controls                                                                                                                                                  array qRT‐PCR                          miR‐148a miR‐375                                                                                       [105](#jcb26445-bib-0105){ref-type="ref"}
  Maria Giulia Egidi 2015          Italy               P              35 urine sediments of PC and 26 benign prostatic hyperplasia (BPH).                                                                                                                                                                                    qRT‐PCR                                miR‐25 miR‐191 miR‐200b miR‐452                                                                        [106](#jcb26445-bib-0106){ref-type="ref"}
  Maria Schubert 2013              Germany Belgium     P              cohort A: 98 high‐risk PC Cohort B: 92 FFPE samples from RP Cohort C: 21 pairs of PC tissues and adjacent benign tissues                                                                                                                               microarray qRT‐PCR                     miR‐146b miR‐181b miR‐361 miR‐515‐3p/5p let‐7a/b/c                                                     [107](#jcb26445-bib-0107){ref-type="ref"}
  Matthew J. Roberts 2015          Australia Germany                  20 specimens 54 non‐cancerous histology and 98 cancer tissues                                                                                                                                                                                          qRT‐PCR                                miR‐125b miR‐200b/c miR‐375                                                                            [108](#jcb26445-bib-0108){ref-type="ref"}
  Robert Mahn 2011                 Germany             P              37 localized PC 18 BPH 8 metastatic PC 20 healthy volunteers 10 PC and adjacent tissues and pre/post prostatectomy serum                                                                                                                               qRT‐PCR                                miR‐16 miR‐26a miR‐32 miR‐195 Let‐7i                                                                   [109](#jcb26445-bib-0109){ref-type="ref"}
  Stefan Ambs 2008                 USA                 P              60 primary prostate tumors and 16 non‐tumor prostate tissues                                                                                                                                                                                           qRT‐PCR microarray                     miR‐1 miR‐32 miR‐106a/106b                                                                             [110](#jcb26445-bib-0110){ref-type="ref"}
  Taha A Haj‐Ahmad 2014            Egypt               PR             8 PC patients, 12 BPH patients and 10 healthy males urine samples                                                                                                                                                                                      microarray qRT‐PCR                     miR‐484 miR‐1825                                                                                       [111](#jcb26445-bib-0111){ref-type="ref"}
  Tong Sun 2012                    USA                 P              86 individuals, prostate tumor tissues from 34 individuals with localized hormone naïve disease, and bone‐derived metastatic CRPC tissues from 17 individuals.                                                                                         qRT‐PCR                                miR‐23b/27b miR‐221/222                                                                                [112](#jcb26445-bib-0112){ref-type="ref"}
  William T. Budd 2015             USA                 P              4 pairs of frozen PC and BPH tissue samples 1 FFPE prostate sample                                                                                                                                                                                     qRT‐PCR                                miR‐22 miR‐125b                                                                                        [113](#jcb26445-bib-0113){ref-type="ref"}
  Xiaoyi Huang 2015                USA                 P              23 CRPC patients 100 CRPC                                                                                                                                                                                                                              sequencing qRT‐PCR                     miR‐375 miR‐1290                                                                                       [30](#jcb26445-bib-0030){ref-type="ref"}
  Yubin Hao 2011                   China               P              20 human prostate specimens (8 prostate cancer tissues and 12 benign prostatic hyperplasia tissues                                                                                                                                                     qRT‐PCR                                miR‐16 miR‐21 miR‐34c miR‐101 miR‐125b miR‐141                                                         [18](#jcb26445-bib-0018){ref-type="ref"}
  Beatriz A. Walter 2013           USA                 P              37 matched prostate tumors, normal epithelium and adjacent stroma. 40 PC 10 N 10stroma                                                                                                                                                                 microarray qRT‐PCR                     34 deregulated                                                                                         [23](#jcb26445-bib-0023){ref-type="ref"}
  Fan Feng 2017                    Spain               R              Dataset (GSE45604) 50 PC and 10 normal specimens urine                                                                                                                                                                                                 data analysis                          7 up 59 down                                                                                           [21](#jcb26445-bib-0021){ref-type="ref"}
  Rihan El Bezawy 2017             Italy               P              44 pairs of PC specimens and normal tissues (GSE76260)                                                                                                                                                                                                 qRT‐PCR                                5 up 13 down                                                                                           [114](#jcb26445-bib-0114){ref-type="ref"}
  Robert K. Nam 2015               Canada.             P              546 prostate cancer                                                                                                                                                                                                                                    qRT‐PCR                                29 up 4 down                                                                                           [115](#jcb26445-bib-0115){ref-type="ref"}
  Yanan Sun 2016                   Nonchina            R              3 microarray studies: 197 samples of PC and 43 samples of normal control                                                                                                                                                                               data analysis                          10 up 19 down                                                                                          [116](#jcb26445-bib-0116){ref-type="ref"}

P, prospective study; R, retrospective study; ISH, in situ hybridization; Refs, references; PC, prostate cancer; BPH, benign prostate hyperplasia; NM, not mentioned; LCM, laser‐captured microdissection; CRPC, castration resistant prostate cancer.

© 2017 Wiley Periodicals, Inc.

2.4. Statistical analysis {#jcb26445-sec-0007}
-------------------------

We drew forest plots to estimate miRNAs expression levels in PC and control patients\' samples, and their effects on PC patients\' OS and RFS. Publication bias was explored by funnel plots.[12](#jcb26445-bib-0012){ref-type="ref"}, [13](#jcb26445-bib-0013){ref-type="ref"} The fixed‐effects model was used to calculate HR and 95% CI in all enrolled studies.[14](#jcb26445-bib-0014){ref-type="ref"} We used Chisquared and the inconsistency index (*I* ^2^) tests to assess the heterogeneities (*P* value ≤0.1 and *I* ^2^ value ≥50 %). To avoid the influence of heterogeneity, subgroup analyses were performed based on the characteristics of included studies, such as patients\' ethnicities, pathological types, and detected sample types, etc. All *P* values were two‐tailed and a *P* value \<0.05 was considered to be statistically significant.

3. RESULTS {#jcb26445-sec-0008}
==========

3.1. Summary of included studies {#jcb26445-sec-0009}
--------------------------------

A total of 1336 primary literatures were searched in PubMed, Embase, Cochrane, and CNKI. As shown in the selection process (Figure [1](#jcb26445-fig-0001){ref-type="fig"}), we firstly removed 49 studies due to duplication. Then, we excluded 980 and 202 studies, respectively, after abstracts and full texts were reviewed. Ultimately, only 104 articles were considered eligible for the meta‐analysis. The characteristics of 104 included studies were summarized in Table [1](#jcb26445-tbl-0001){ref-type="table-wrap"} in alphabetical order of the miRNAs. The publication years of these records ranged from 2007 to 2017. In these 104 studies, some were divided into several parts because of multiple miRNAs. Data of enrolled records were collected from the United States, China, Germany, Greece, Italy, Austria, Korea, and Brazil, etc. The dominant ethnicity was Caucasian in more than half of studies, while 38‐2 studies were executed in Asians. Most studies were prospective in design. The expression level of miRNA was usually detected by quantitative real‐time polymerase chain reaction (qRT‐PCR) and microarray in tissue samples, while 6 + 2 studies were in serum or plasma samples, 6 + 2 studies were in urine (Table [1](#jcb26445-tbl-0001){ref-type="table-wrap"}). Among these studies, 71 records were associated with Mean ± SD and fold‐change of miRNA expression level in tumor or control samples (Table [2](#jcb26445-tbl-0002){ref-type="table-wrap"} and Figures [2](#jcb26445-fig-0002){ref-type="fig"}, [3](#jcb26445-fig-0003){ref-type="fig"}, [4](#jcb26445-fig-0004){ref-type="fig"}, [5](#jcb26445-fig-0005){ref-type="fig"}). A 29 focused on RFS (Table [3](#jcb26445-tbl-0003){ref-type="table-wrap"} and Figure [6](#jcb26445-fig-0006){ref-type="fig"}A‐E), and 11 focused on OS (Table [4](#jcb26445-tbl-0004){ref-type="table-wrap"} and Figure [6](#jcb26445-fig-0006){ref-type="fig"}F). In the analysis of RFS and OS, 26, and 9 records directly reported HRs and 95% CIs, respectively, while in other studies we extrapolated these necessary variables by available original data (Tables [3](#jcb26445-tbl-0003){ref-type="table-wrap"}, 4 and Figure [6](#jcb26445-fig-0006){ref-type="fig"}).

###### 

The expression levels of miRNAs

  miRNA          Samples                                                                                                                                                      Mean ± SD (PC vs control)                                                                     Fold change (PC/control)   *P* value   Refs
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- -------------------------- ----------- -------------------------------------------
  miR‐7          20 pairs of tumors and adjacent normal tissues                                                                                                               1.7 ± 1.04 vs 1.21 ± 0.55                                                                                                0.6569      [33](#jcb26445-bib-0033){ref-type="ref"}
  miR‐7‐2\*      44 pairs of PC and normal                                                                                                                                                                                                                                  0.806642                   2.19E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐7c         50 PC and 10 normal                                                                                                                                                                                                                                        0.001272                   1.56E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐9          51 localized PC                                                                                                                                              0.96 ± 0.89 vs 1.34 ± 2.47                                                                                               0.637       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐9‐1        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.9 vs 4.98                                                                                                              0.04723     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐9‐2        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.89 vs 4.97                                                                                                             0.04892     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐9‐3        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  6.12 vs 4.96                                                                                                             0.01907     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐15b        40 PC and 10 normal                                                                                                                                                                                                                                        3.4761                     0.0418      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐18b        40 PC and 10 normal                                                                                                                                                                                                                                        6.8061                     0.0133      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐20b        40 PC and 10 normal                                                                                                                                                                                                                                        3.1928                     0.0501      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐22         4 frozen tissue samples 1 FFPE prostate sample                                                                                                                                                                                                             3.2                        NM          [113](#jcb26445-bib-0113){ref-type="ref"}
  miR‐24         50 PC and 10 normal                                                                                                                                                                                                                                        0.27                       3.68E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐24‐2       50 PC and 10 normal                                                                                                                                                                                                                                        0.164459                   9.76E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐26a‐5p     140 pairs of fresh PC tissues and normal tissues                                                                                                             0.058 ± 0.016 vs 0.115 ± 0.043                                                                                           \<0.001     [45](#jcb26445-bib-0045){ref-type="ref"}
  miR‐28‐3p      50 PC and 10 normal                                                                                                                                                                                                                                        0.00668                    1.08E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐28‐5p      50 PC and 10 normal                                                                                                                                                                                                                                        0.003839                   3.28E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐29b        51 localized PC                                                                                                                                              0.51 ± 0.64 vs 0.56 ± 0.77                                                                                               0.852       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐30a        51 localized PC                                                                                                                                              6.37 ± 7.91 vs 1.7 ± 2.77                                                                                                0.039       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐30c‐1      50 PC and 10 normal                                                                                                                                                                                                                                        0.257951                   3.18E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐30d        56 pairs of primary PC and control                                                                                                                           7.95 ± 7.03 vs 6.23 ± 6.06                                                                                               0.03        [48](#jcb26445-bib-0048){ref-type="ref"}
  miR‐30e\*      44 pairs of PC and normal                                                                                                                                                                                                                                  0.840896                   4.10E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐33a        Paired prostate cancer tissue and adjacent normal tissue                                                                                                                                                                                                   0.1389                     \<0.01      [50](#jcb26445-bib-0050){ref-type="ref"}
  miR‐34c‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.17691                    7.42E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐34c‐5p     40 PC and 10 normal                                                                                                                                                                                                                                        8.0395                     0.0283      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐92a        40 PC and 10 normal                                                                                                                                                                                                                                        3.0015                     0.0177      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐93         197 PC and 43 normal                                                                                                                                                                                                                                       2.14                       1.69E‐09    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐96         197 PC and 43 normal                                                                                                                                                                                                                                       2.35                       2.33E‐12    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐101        8 PC and 12 BPH                                                                                                                                                                                                                                            0.91                       \>0.05      [18](#jcb26445-bib-0018){ref-type="ref"}
  miR‐122        40 PC and 10 normal                                                                                                                                                                                                                                        5.5663                     0.0054      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐126        128 PCa                                                                                                                                                      1.05 ± 0.63 vs 2.92 ± 0.98                                                                                               \<0.001     [55](#jcb26445-bib-0055){ref-type="ref"}
  miR‐126‐5p     12 G \> 7, 12 G7, and 12 non‐cancerous samples                                                                                                                                                                                                             2.22                       \<0.05      [97](#jcb26445-bib-0097){ref-type="ref"}
  miR‐128        128 PC tissue and serum and matched normal                                                                                                                   1.05 ± 0.63 vs 2.92 ± 0.98                                                                                               \<0.001     [56](#jcb26445-bib-0056){ref-type="ref"}
  miR‐128a       40 PC and 10 normal                                                                                                                                                                                                                                        4.5004                     0.0143      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐130b       197 PC and 43 normal                                                                                                                                                                                                                                       1.974463                   3.52E‐07    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐134        40 PC and 10 normal                                                                                                                                                                                                                                        23.1323                    0.0125      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐135b       40 PC and 10 normal                                                                                                                                                                                                                                        4.0019                     0.0141      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐138‐2      18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.23 vs 4.25                                                                                                             0.03941     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐139        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  7.24 vs 8.08                                                                                                             0.03061     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐146b‐5p    40 PC and 10 normal                                                                                                                                                                                                                                        3.5577                     0.0019      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐148b       40 PC and 10 normal                                                                                                                                                                                                                                        2.8135                     0.0358      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐149        44 pairs of PC and normal                                                                                                                                                                                                                                  0.796                      0.416       [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐151a‐5p    12 G \> 7, 12 G7, and 12 non‐cancerous samples                                                                                                                                                                                                             2.02                       \<0.05      [97](#jcb26445-bib-0097){ref-type="ref"}
  miR‐153        197 PC and 43 normal                                                                                                                                                                                                                                       3.1425                     2.74E‐13    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐155        51 localized PC                                                                                                                                              3.12 ± 4.56 vs 2.09 ± 3.8                                                                                                0.463       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐181d       50 PC and 10 normal                                                                                                                                                                                                                                        0.062341                   9.34E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐182‐5p     patient set 1:69 PC patient set 2:10 PC                                                                                                                      Patient set 1: 1.745 ± 0.278 vs 0.864 ± 0.136 Patient set 2: 1.863 ± 0.381 vs 0.761 ± 0.158                              0.021       [66](#jcb26445-bib-0066){ref-type="ref"}
  miR‐183\*      44 pairs of PC and normal                                                                                                                                                                                                                                  1.505247                   7.68E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐184        40 PC and 10 normal                                                                                                                                                                                                                                        4.0633                     0.0086      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐188        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  8.48 vs 7.5                                                                                                              0.01878     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐188‐5p     180 pairs of PC and normal                                                                                                                                                                                                                                 0.0956                     NM          [68](#jcb26445-bib-0068){ref-type="ref"}
  miR‐193a‐5p    40 PC and 10 normal                                                                                                                                                                                                                                        4.5984                     0.0094      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐193b       40 PC and 10 normal                                                                                                                                                                                                                                        12.649                     0.0021      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐199a‐1     50 PC and 10 normal                                                                                                                                                                                                                                        0.451942                   2.06E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐199a‐3p    50 PC and 10 normal                                                                                                                                                                                                                                        0.000759                   1.08E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐214        40 PC and 10 normal                                                                                                                                                                                                                                        9.9075                     0.0055      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐215        40 PC and 10 normal                                                                                                                                                                                                                                        8.4863                     0.038       [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐220a       44 pairs of PC and normal                                                                                                                                                                                                                                  0.907519                   0.355       [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐221‐3p     12 G \> 7, 12 G7, and 12 non‐cancerous samples                                                                                                                                                                                                             5.47                       \<0.05      [97](#jcb26445-bib-0097){ref-type="ref"}
  miR‐222‐3p     12 G \> 7, 12 G7, and 12 non‐cancerous samples                                                                                                                                                                                                             3.88                       \<0.05      [97](#jcb26445-bib-0097){ref-type="ref"}
  miR‐223        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  10.66 vs 11.9                                                                                                            0.00179     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐223‐3p     10 pairs of PC and adjacent non‐cancerous tissues                                                                                                            2.98 ± 1.45 vs 1.55 ± 0.38                                                                                               \<0.01      [75](#jcb26445-bib-0075){ref-type="ref"}
  miR‐296        TMA100: 100 PC cases TMA96: 96 cases                                                                                                                         1.79 ± 0.19 vs 2.71 ± 0.16                                                                                               \<0.05      [79](#jcb26445-bib-0079){ref-type="ref"}
  miR‐296‐5p     44 pairs of PC and normal                                                                                                                                                                                                                                  0.646176                   1.49E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐301b       18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.61 vs 3.65                                                                                                             0.02116     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐320c‐2     18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  3.54 vs 2.39                                                                                                             0.0393      [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐324‐5p     197 PC and 43 normal                                                                                                                                                                                                                                       0.565156                   2.06E‐05    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐328        197 PC and 43 normal                                                                                                                                                                                                                                       0.511                      7.85E‐07    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐335        20 pairs of primary PC and adjacent 104 PC and 20 benign                                                                                                     3.27 ± 0.99 vs. 4.55 ± 1.34                                                                                              \<0.05      [82](#jcb26445-bib-0082){ref-type="ref"}
  miR‐338‐5p     50 PC and 10 normal                                                                                                                                                                                                                                        14.70974                   9.88E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐362‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.265027                   3.18E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐372        40 PC and 10 normal                                                                                                                                                                                                                                        6.8639                     0.0184      [23](#jcb26445-bib-0023){ref-type="ref"}
  miR‐373        51 localized PC                                                                                                                                              0.26 ± 0.37 vs. 0.29 ± 0.32                                                                                              0.186       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐376a       50 PC and 10 normal                                                                                                                                                                                                                                        0.457502                   1.41E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐378\*      197 PC and 43 normal                                                                                                                                                                                                                                       0.476022                   1.64E‐08    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐378c       50 PC and 10 normal                                                                                                                                                                                                                                        0.011878                   1.40E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐381        50 PC and 10 normal                                                                                                                                                                                                                                        0.20897                    2.30E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐383        TCGA:187 primary PC validation cohort: 112 pairs of PC and adjacent normals                                                                                                                                                                                0.25                       0.05        [84](#jcb26445-bib-0084){ref-type="ref"}
  miR‐411        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  3.83 vs 2.73                                                                                                             0.02673     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐421        50 PC and 10 normal                                                                                                                                                                                                                                        0.03487                    6.02E‐04    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐422a       50 PC and 10 normal                                                                                                                                                                                                                                        0.014149                   8.65E‐05    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐424        50 PC and 10 normal                                                                                                                                                                                                                                        0.088399                   2.94E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐429        51 localized PC                                                                                                                                              7.74 ± 7.34 vs 7.75 ± 17.18                                                                                              0.998       [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐433        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.21 vs 3.15                                                                                                             0.030601    [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐455‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.001986                   2.07E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐455‐5p     50 PC and 10 normal                                                                                                                                                                                                                                        0.093956                   9.76E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐485‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.2564                     1.82E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐486        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.49 vs 5.6                                                                                                              0.03746     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐486‐5p     12 G \> 7, 12 G7, and 12 non‐cancerous samples                                                                                                                                                                                                             0.3937                     \<0.05      [97](#jcb26445-bib-0097){ref-type="ref"}
  miR‐487b       197 PC and 43 normal                                                                                                                                                                                                                                       0.565379                   3.69E‐05    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐489        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  3.66 vs 2.67                                                                                                             0.02183     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐490‐5p     50 PC and 10 normal                                                                                                                                                                                                                                        0.184615                   1.56E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐495        51 localized PC                                                                                                                                              0.77 ± 0.39 vs 0.93 ± 0.32                                                                                               0.78        [15](#jcb26445-bib-0015){ref-type="ref"}
  miR‐497        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  11.19 vs 10.28                                                                                                           0.01111     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐501        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.74 vs 4.91                                                                                                             0.00525     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐502‐5p     197 PC and 43 normal                                                                                                                                                                                                                                       0.573804                   3.86E‐05    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐503        50 PC and 10 normal                                                                                                                                                                                                                                        0.376508                   1.41E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐507        PC and matched Normal                                                                                                                                                                                                                                      0.858565                   4.88E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐509‐3‐5p   50 PC and 10 normal                                                                                                                                                                                                                                        0.318223                   3.62E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐509‐5p     20 PC, 20 tumor‐adjacent tissues, and 20 normal prostate tissues                                                                                             0.314 ± 0.048 vs 1.532 ± 0.015                                                                                           \<0.05      [87](#jcb26445-bib-0087){ref-type="ref"}
  miR‐518b       44 pairs of PC and normal                                                                                                                                                                                                                                  0.779165                   4.23E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐543        50 PC and 10 normal                                                                                                                                                                                                                                        0.270522                   1.08E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐545        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.1 vs 4.04                                                                                                              0.00524     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐574‐3p     48 pairs of PC and adjacent non‐cancerous tissues                                                                                                                                                                                                          0.5                        \<0.0001    [89](#jcb26445-bib-0089){ref-type="ref"}
  miR‐612        44 pairs of PC and normal                                                                                                                                                                                                                                  1.658639                   5.31E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐624        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.66 vs 4.07                                                                                                             0.030601    [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐628‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.04014                    1.80E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐650        216 PC, 324 benign, and 77 control 22 PC, 20 benign, and 11 control                                                                                          1.29 ± 0.08 vs 1.07 ± 0.05                                                                                               0.012       [90](#jcb26445-bib-0090){ref-type="ref"}
  miR‐652        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  8.3 vs 6.73                                                                                                              0.00124     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐659        44 pairs of PC and normal                                                                                                                                                                                                                                  0.795536                   4.10E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐663        197 PC and 43 normal                                                                                                                                                                                                                                       0.545382                   2.62E‐09    [116](#jcb26445-bib-0116){ref-type="ref"}
  miR‐671        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  7.75 vs 6.94                                                                                                             0.00072     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐708        18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  6.67 vs 5.45                                                                                                             0.01206     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐875‐3p     50 PC and 10 normal                                                                                                                                                                                                                                        0.383402                   3.12E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐875‐5p     44 pairs of PC and normal                                                                                                                                                                                                                                  0.632878                   1.31E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐887        50 PC and 10 normal                                                                                                                                                                                                                                        0.211747                   2.33E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐1184       50 PC and 10 normal                                                                                                                                                                                                                                        3.450542                   1.56E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐1206       44 pairs of PC and normal                                                                                                                                                                                                                                  0.907519                   2.68E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐1207‐3p    PC patients of 389 CA and 15 AA                                                                                                                              Black: 3.00 ± 2.65 White 5.36 ± 3.76                                                                                     0.062       [93](#jcb26445-bib-0093){ref-type="ref"}
  miR‐1207‐5p    50 PC and 10 normal                                                                                                                                                                                                                                        180.2841                   4.72E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐1228       44 pairs of PC and normal                                                                                                                                                                                                                                  1.086735                   4.90E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐1238       50 PC and 10 normal                                                                                                                                                                                                                                        0.883057                   2.36E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐1244       44 pairs of PC and normal                                                                                                                                                                                                                                  1.484524                   5.20E‐03    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐1245       44 pairs of PC and normal                                                                                                                                                                                                                                  1.265757                   3.01E‐02    [114](#jcb26445-bib-0114){ref-type="ref"}
  miR‐1248       18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  8.91 vs 7.77                                                                                                             0.01907     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐1249       18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  5.37 vs 4.47                                                                                                             0.00622     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐1271       50 PC and 10 normal                                                                                                                                                                                                                                        0.02573                    3.28E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐1302‐1     18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.53 vs 2.75                                                                                                             0.01529     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐1302‐3     18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.42 vs 2.75                                                                                                             0.01529     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐1302‐7     18 PC with recurrence and 13 PC no metastasis no recurrence                                                                                                  4.19 vs 2.55                                                                                                             0.02113     [115](#jcb26445-bib-0115){ref-type="ref"}
  miR‐3200‐3p    50 PC and 10 normal                                                                                                                                                                                                                                        0.40029                    4.48E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐4288       50 PC and 10 normal                                                                                                                                                                                                                                        0.219167                   3.76E‐03    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐4328       50 PC and 10 normal                                                                                                                                                                                                                                        0.470068                   4.96E‐02    [21](#jcb26445-bib-0021){ref-type="ref"}
  miR‐4638‐5p    3 CRPC and 3 ADPC 18 CRPC and 30 ADPC                                                                                                                                                                                                                      0.4167 0.2128              1.44E‐08    [95](#jcb26445-bib-0095){ref-type="ref"}
  let‐7b         Cohort A: 6 BPH tissues and 13 high‐risk PC specimens Cohort B: 92 FFPE PC samples Cohort C: 21 pairs of fresh frozen PC tissue and adjacent benign tissue   3.16 ± 0.76 vs 3.8 ± 0.37                                                                                                \<0.01      [107](#jcb26445-bib-0107){ref-type="ref"}

Refs, reference; PC, prostate cancer; BPH, benign prostate hyperplasia; CRPC, castration resistant prostate cancer.

© 2017 Wiley Periodicals, Inc.

![Forest plots showing mean expression levels of different miRNAs with corresponding heterogeneity statistics. (A) miR‐1; (B) miR‐23b; (C) miR‐27b; (D) miR‐34a; (E) miR‐34b; (F) miR‐34c; (G) miR‐99b; (H) miR‐106b; (I) miR‐125b; (J) miR‐152; (K) miR‐183; (L) miR‐187; (M) miR‐199a; (N) miR‐200a; (O) miR‐200b; (P) miR‐204; (Q) miR‐205; (R) miR‐224; (S) miR‐301a; (T) miR‐452; (U) miR‐454; (V) miR‐505. Squares and horizontal lines correspond to study‐specific HRs and 95% CIs; respectively. The area of the squares correlates the weight of each enrolled study and the diamonds represent the summary HRs and 95% CIs](JCB-119-2763-g003){#jcb26445-fig-0002}

![Forest plots of subgroup analyses stratified by ethnicities; main pathologic types and detected samples; showing mean expression levels or fold change with corresponding heterogeneity statistics. (A) miR‐15a; (B) miR‐16; (C) forest plot and funnel plot of miR‐21; each point represents a separate study for publication bias test in funnel plot; (D) miR‐25; (E) miR‐32; (F) miR‐100; (G) miR‐141; (H) miR‐143; (I) miR‐145; (J) miR‐191; (K) miR‐200c; (L) miR‐221; (M) miR‐222; (N) miR‐375; (O) let‐7c. Squares and horizontal lines correspond to study‐specific HRs and 95% CIs; respectively. The area of the squares correlates the weight of each enrolled study and the diamonds represent the summary HRs and 95% CIs](JCB-119-2763-g004){#jcb26445-fig-0003}

![Forest plots showing mean expression levels of miRNAs with corresponding heterogeneity statistics. (A) miR‐10b; (B) miR‐18a; (C) miR‐30c; (D) miR‐139‐5p; (E) miR‐146a; (F) miR‐182; (G) miR‐206. Squares and horizontal lines correspond to study‐specific HRs and 95% CIs; respectively. The area of the squares correlates the weight of each enrolled study and the diamonds represent the summary HRs and 95% CIs](JCB-119-2763-g005){#jcb26445-fig-0004}

![Forest plots showing mean expression levels of miRNAs with significant heterogeneity. (A) miR‐31; (B) miR‐124; (C) miR‐125a; (D) miR‐133a; (E) miR‐133b; (F) miR‐154; (G) miR‐181a; (H) miR‐181b; (I) miR‐181c; (J) miR‐203; (K) miR‐210; (L) miR‐218; (M) miR‐378; (N) miR‐548c. Squares and horizontal lines correspond to study‐specific HRs and 95% CIs; respectively. The area of the squares correlates the weight of each enrolled study and the diamonds represent the summary HRs and 95% CIs](JCB-119-2763-g006){#jcb26445-fig-0005}

###### 

The recurrence‐free survival of miRNAs in enrolled studies

  miRNA         Samples                                                                                                                                                      RFS HR/RR (95%CI)                                                  *P* value   Refs
  ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------ ----------- -------------------------------------------
  miR‐10b       52 primary PC and normal adjacent tissues (24 early biochemical relapse and 22 no/ late biochemical relapse)                                                 2.15 (1.02‐4.51)                                                   0.044       [34](#jcb26445-bib-0034){ref-type="ref"}
  miR‐23a       3 pairs of primary prostate cancer and adjacent non‐tumor tissues 20 paired of prostate cancer and adjacent non‐tumor tissues. 123 prostate cancer tissues   0.389 (0.249‐0.608)                                                \<0.0001    [41](#jcb26445-bib-0041){ref-type="ref"}
  miR‐23b       118 pairs of PC and control 27 BPH and 20 tumor samples 48 samples                                                                                           6 (3‐13)                                                           \<0.002     [43](#jcb26445-bib-0043){ref-type="ref"}
  miR‐27b       41 noncancerous tissues and 49 PC tissues                                                                                                                    0.255 (0.069‐0.944)                                                0.0407      [44](#jcb26445-bib-0044){ref-type="ref"}
  miR‐34b       148 LCM matched human tissue samples 27 BPH and 20 tumor samples                                                                                             3.3 (1.3‐8.7)                                                      \<0.02      [51](#jcb26445-bib-0051){ref-type="ref"}
  miR‐106b      28 non‐cancerous tissues, 99 primary tumors, and 14 distant metastases/recurrence.                                                                           2.7 (1.1‐7.3)                                                      0.014       [53](#jcb26445-bib-0053){ref-type="ref"}
  miR‐100       49 prostate cancer (28 men without and 21 with biochemical recurrence)                                                                                       3.045 (1.200‐7.737)                                                0.019       [27](#jcb26445-bib-0027){ref-type="ref"}
  miR‐133b      135 PC, 18 prostatic intraepithelial neoplasia (PIN), and 25 normals                                                                                         1.775 (1.013‐3.108)                                                0.045       [59](#jcb26445-bib-0059){ref-type="ref"}
  miR‐150       167 PC 4 pairs of PC and adjacent normal tissues                                                                                                             1.90 (1.21‐2.98)                                                   0.005       [63](#jcb26445-bib-0063){ref-type="ref"}
  miR‐191       49 prostate cancer (28 men without and 21 with biochemical recurrence)                                                                                       2.642 (1.030‐6.780)                                                0.043       [27](#jcb26445-bib-0027){ref-type="ref"}
  miR‐205       Study cohort: 105 HRPC, 10 BHP validation cohort:78 HRPCa                                                                                                    Study cohort: 2.01(0.83‐4.85) Validation cohort: 0.82 (0.39‐1.7)   0.596       [71](#jcb26445-bib-0071){ref-type="ref"}
  miR‐221       28 recurrent and 37 non‐recurrent prostate cancer cases                                                                                                      0.71 (0.32‐1.61)                                                   0.42        [28](#jcb26445-bib-0028){ref-type="ref"}
  miR‐222       28 recurrent and 37 non‐recurrent prostate cancer cases                                                                                                      0.51 (0.22‐1.18)                                                   0.12        [28](#jcb26445-bib-0028){ref-type="ref"}
  miR‐224       4 and 20 pairs of primary PC and adjacent non‐tumor frozen samples TMA: 114 PC tissues respectively from Caucasian and African‐American PC patients          0.31 (0.11‐0.86)                                                   0.017       [78](#jcb26445-bib-0078){ref-type="ref"}
  miR‐301a      585 prostate cancer                                                                                                                                          1.42 (1.06‐1.90)                                                   0.002       [81](#jcb26445-bib-0081){ref-type="ref"}
  miR‐383       TCGA database: 187 primary PC validation cohort: 112 PC FFPE tissues and matched adjacent normals                                                            TCGA database: 0.661 Validation cohort: 0.897                      0.0655      [84](#jcb26445-bib-0084){ref-type="ref"}
  miR‐449b      36 PC 163 radical prostatectomy patients 40 patients (20 recurrent and 20 non‐recurrent patients)                                                            1.9                                                                0.003       [85](#jcb26445-bib-0085){ref-type="ref"}
  miR‐466       48 pairs of LCM tissue samples validation cohort: 56 PC                                                                                                      17 (5‐50)                                                          0.02        [86](#jcb26445-bib-0086){ref-type="ref"}
  miR‐663       127 prostate cancer and 10 benign prostatic hyperplasia (BPH)                                                                                                2.924 (1.981‐4.316)                                                \<0.001     [91](#jcb26445-bib-0091){ref-type="ref"}
  miR‐708       40 PC and 8 normal 96 paired of PC and normal                                                                                                                6 (2.2‐16.4)                                                       0.0138      [92](#jcb26445-bib-0092){ref-type="ref"}
  miR‐1207‐3p   PC patients of 389 CA and 15 moAA                                                                                                                            1.8 (0.8‐4.3)                                                      \<0.001     [93](#jcb26445-bib-0093){ref-type="ref"}
  miR‐3622b     100 pairs of PC and adjacent normals                                                                                                                         0.407                                                              0.2         [94](#jcb26445-bib-0094){ref-type="ref"}
  let‐7b        cohort A: 98 high‐risk PC Cohort B: 92 FFPE samples cohort C: 21 pairs of PC and adjacent benign tissue                                                      0.36 (0.161‐0.823)                                                 0.02        [107](#jcb26445-bib-0107){ref-type="ref"}

RFS, recurrence free survival; HR, hazard ratio; CI, confidence interval; Refs, reference; PC, prostate cancer; BPH, benign prostate hyperplasia; CRPC, castration resistant prostate cancer.

© 2017 Wiley Periodicals, Inc.

![Forest plots for merged analyses of recurrence‐free survival (RFS) and overall survival (OS) associated with different miRNAs expression. Forest plots for RFS analyses of (A) miR‐21 (B) miR‐30c; (C) miR‐129; (D) miR‐145; (E) let‐7c; (F) Forest plots of OS analyses of miR‐375. Squares and horizontal lines correspond to study‐specific HRs and 95% CIs; respectively. The area of the squares correlates the weight of each enrolled study and the diamonds represent the summary HRs and 95% CIs](JCB-119-2763-g007){#jcb26445-fig-0006}

###### 

The overall survival of miRNAs in enrolled studies

  miRNA         Samples                                                                                                                                                      OS HR/RR (95%CI)                            *P* value   Refs
  ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------- ----------- ------------------------------------------
  miR‐23a       3 pairs of primary prostate cancer and adjacent non‐tumor tissues 20 paired of prostate cancer and adjacent non‐tumor tissues. 123 prostate cancer tissues   0.389 (0.249‐0.608)                         \<0.001     [41](#jcb26445-bib-0041){ref-type="ref"}
  miR‐23b       118 pairs of PCs and controls 27 BPH and 20 tumor samples 48 samples                                                                                         3.3 (4‐19)                                  \<0.0001    [43](#jcb26445-bib-0043){ref-type="ref"}
  miR‐132       Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                      1.9 (1.1‐3.4)                               0.02        [29](#jcb26445-bib-0029){ref-type="ref"}
  miR‐150       167 PC 4 pairs of PC and adjacent normal tissues                                                                                                             1.87 (1.19‐2.94)                            0.006       [63](#jcb26445-bib-0063){ref-type="ref"}
  miR‐200a      Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                      2.1 (1.2‐3.6)                               0.009       [29](#jcb26445-bib-0029){ref-type="ref"}
  miR‐200b      Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                      3.8 (2.0‐6.9)                               0.000006    [29](#jcb26445-bib-0029){ref-type="ref"}
  miR‐200c      Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                      3.8 (2.0‐6.9)                               0.005       [29](#jcb26445-bib-0029){ref-type="ref"}
  miR‐205       Study cohort: 105 HRPC, 10 BPH validation cohort: 78 HRPC                                                                                                    Study cohort: 2.04 Validation cohort: 3.1   0.0817      [71](#jcb26445-bib-0071){ref-type="ref"}
  miR‐221       cohort 1: 134 PC cohort 2: 89 PC                                                                                                                             cohort 1: 0 cohort 2: 0.029                 \<0.0001    [74](#jcb26445-bib-0074){ref-type="ref"}
  miR‐224       4 and 20 pairs of primary PC and adjacent non‐tumor Taylor dataset: 149 primary PC tissues and 29 adjacent non‐cancerous prostate tissues                    0.73 (0.31‐1.72)                            0.046       [76](#jcb26445-bib-0076){ref-type="ref"}
  miR‐429       Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients                                                                                                      3.3 (1.8‐6.0)                               0.00005     [29](#jcb26445-bib-0029){ref-type="ref"}
  miR‐708       40 PC and 8 normal 96 pairs of PC and normal                                                                                                                 6 (2.2‐16.4)                                0.0223      [92](#jcb26445-bib-0092){ref-type="ref"}
  miR‐1207‐3p   PC patients of 389 CA and 15 AA                                                                                                                              1.8 (0.8‐4.3)                               0.062       [93](#jcb26445-bib-0093){ref-type="ref"}
  miR‐1290      23 CRPC patients 100 CRPC                                                                                                                                    1.79 (1.30‐2.48)                            \<0.004     [30](#jcb26445-bib-0030){ref-type="ref"}

OS,overall survival; HR, hazard ratio; CI, confidence interval; Refs, reference; PC, prostate cancer; BPH, benign prostate hyperplasia; CRPC, castration resistant prostate cancer.

© 2017 Wiley Periodicals, Inc.

3.2. miRNAs and PC diagnosis {#jcb26445-sec-0010}
----------------------------

miRNAs may regulate the wide range of biologic processes, and their deregulation are associated with PC onset, progression, and metastasis. More and more studies investigated differentially expressed miRNA as PC diagnostic and prognostic markers by comparing the expression levels of miRNAs in tumor tissues to that in BPH or normal controls. But there were the high variability in the data obtained from the different records. These could be caused by several factors as follows: (i) different sample groups; (ii) different detecting and verifying methods; (iii) small sample size. Nonetheless, these studies depicted a starting point, and some of the included records screened the same miRNA which was found with the same trend in multiple studies with different methods, as shown in Table [1](#jcb26445-tbl-0001){ref-type="table-wrap"}. However, a confirmed diagnostic miRNA which could be translated into the clinic was not arised. Further confirmed experiments are needed in additional large patient cohorts.

In Figure [2](#jcb26445-fig-0002){ref-type="fig"}, 22 miRNAs were reported to be consistently deregulated in different records. Among them, 6 miRNAs (miR‐34a, miR‐106b, miR‐183, miR‐200a/b, and miR‐301a) were up‐regulated in PC, while 16 miRNAs (miR‐1, miR‐23b, miR‐27b, miR‐34b/c, miR‐99b, miR‐125b, miR‐152, miR‐187, miR‐199a, miR‐204, miR‐205, miR‐224, miR‐452, miR‐454, and miR‐505) were down‐regulated. miR‐125b, miR‐205, miR‐1, and miR‐23b were the most commonly detected to evaluate their diagnostic efficacy between PC patients and non‐cancerous individuals. In the studies about the most obviously up‐regulated miR‐200a and miR‐200b, the pooled expression values were 5.17 (95%CI 3.22‐7.13) and 4.08 (95%CI 2.91‐5.24), respectively (Figures [2](#jcb26445-fig-0002){ref-type="fig"}N and [2](#jcb26445-fig-0002){ref-type="fig"}O). While miR‐199a was most significantly down‐regulated, which pooled value was −4.23 (95%CI −16.22, 7.76) (Figure [2](#jcb26445-fig-0002){ref-type="fig"}M). More potential biomarkers were summarized in Table [2](#jcb26445-tbl-0002){ref-type="table-wrap"}, 134 PC related miRNAs were listed which had the diagnostic potential to be aberrantly expressed in PC patients compared with healthy controls. A 60 up‐regulated miRNAs and 63 down‐regulated miRNAs were able to discriminate PC patients from BPH or healthy individuals. The remaining 11 miRNAs were not statistically significant in the studies. Any miRNA‐based clinical screening still lacks a consensus signature to be applied in the routine assay, and needs further validation in an intended use population.

3.3. Publication bias and subgroup analysis {#jcb26445-sec-0011}
-------------------------------------------

The high heterogeneity between the data from the included records could be associated with several factors: different study design, different races of patients, different methods of sample collection and detection, incomplete information, and small sample size. There were also many difficultly statistical factors: proportion of contaminating cells, limited tumor size and differences in miRNAs stability and processing. In addition, different control samples (BPH or adjacent normal or unmatched normal) and the different characteristics of PC (low/high‐risk or metastasis or recurrence) could explain, at least in part, the different results. Significant heterogeneities (*P *\< 0.05, *I* ^2 ^\> 50%) were found in most miRNAs expression profiles, we performed the subgroup analyses to seek the source of heterogeneity, which include ethnicity, sources of control (BPH or N), and sample types (serum/plasma or urine), etc.

To assess publication bias of 11 studies on miR‐21, the funnel plot was drawed. As shown in the Figure [3](#jcb26445-fig-0003){ref-type="fig"}C, significant publication bias was found in the pooled analysis of miR‐21 (*P *\< 0.00001, *I* ^2^ = 95%), most of the research data was distributed on the edge line. In order to avoid the effect of heterogeneity, we performed four subgroup analyses divided by ethnicity, and sample categories, including: China, Brazil, local versus meta, and PC versus control. Unfortunately, the heterogeneities were significantly reduced in Brazil subgroup and local versus meta subgroup, while the expression of miR‐21 in other subgroups still had obvious heterogeneity. In Brazil subgroup, I2 value was less than 50%, but SD value from the first study by Betina Katz[15](#jcb26445-bib-0015){ref-type="ref"}was too large, and covered the scope of the other two data. Therefore, we believe that the study on miR‐21 still needs to be further expanded. We did not find corresponding increased miR‐21 in Chinese by merging four studies[16](#jcb26445-bib-0016){ref-type="ref"}, [17](#jcb26445-bib-0017){ref-type="ref"}, [18](#jcb26445-bib-0018){ref-type="ref"}, [19](#jcb26445-bib-0019){ref-type="ref"} (Figure [3](#jcb26445-fig-0003){ref-type="fig"}C). When stratified by the category of detected samples, increased expression of miR‐21 showed consistency in local versus meta subgroup, but no statistically significant result was observed in PC versus control subgroup.

Five studies on miR‐100 had obvious heterogeneity, as shown in the Figure [3](#jcb26445-fig-0003){ref-type="fig"}F. After carefully reviewing the five full‐texts, they were divided into three subgroups, including: Brazil, urine and recurrence and non‐recurrence. Among them, heterogeneity in the Brazil subgroup was significantly reduced (*P* = 0.24, *I* ^2^ = 26%). Subgroup analysis of miR‐141 expression showed that miR‐141 expression was consistently up‐regulated in four studies of PC versus control subgroup and more obviously up‐regulated in serum samples data from Heather H. Cheng.[20](#jcb26445-bib-0020){ref-type="ref"} Four studies on miR‐200c had also obvious heterogeneity, as shown in the Figure [3](#jcb26445-fig-0003){ref-type="fig"}K. Three subgroups: PC versus control, serum and urine were classified according to different sample characteristics. Fan feng et al[21](#jcb26445-bib-0021){ref-type="ref"} collected the serum samples from 50 PC patients and 10 normal controls, while Heather H, Cheng et al[20](#jcb26445-bib-0020){ref-type="ref"} detected the miR‐200c expression levels in patients\' urine samples. The heterogeneity of miR‐200c expression in PC versus control subgroup significantly reduced (*P* = 0.98, I2 = 0%). Six studies on miR‐221 were divided into four subgroups: local versus meta, aggressive versus non‐aggressive, PC versus control and urine, and the heterogeneity in PC versus control subgroup was significantly reduced to 0%. In addition, existing data showed that the expression of miR‐221 in primary PC was less than that in normal tissues, but miR‐221 was significantly increased when PC progressed to more malignant stages (metastasis or recurrence or hormone resistance). Among them, Tong\'s research data were divided into two parts, which were included in local versus meta subgroup and PC versus control subgroup, respectively. The studies on miR‐15a and miR‐16 were divided into two subgroups: PC versus meta, PC versus control. Results showed that both of miR‐15a and miR‐16 were up‐regulated in metastasis PC, while their expression levels were lower in PC tissues than in non‐cancerous tissues. Inconsistently expression of let‐7c was reported. The three studies on let‐7c were divided into two subgroups: high‐risk versus meta and high‐risk versus control, and the research data from Katia R. M. Leite 2013[22](#jcb26445-bib-0022){ref-type="ref"} were separately counted in the two subgroups because two sets of data were involved. The heterogeneity was significantly reduced to 0% and 12%. The study of miR‐143, 145 191, −25‐32 was divided into two subgroups, PC versus meta, PC versus control. Moreover, miR‐222 and miR‐375 were inconsistently expressed in prostate tumor tissues and matched normal tissues (Figures [3](#jcb26445-fig-0003){ref-type="fig"}M and [3](#jcb26445-fig-0003){ref-type="fig"}N). So it was essential to conduct subgroup analyses on miR‐222 and miR‐375 expression. Five studies on miR‐222 could be divided into three subgroups: PC versus control, China, and urine. The study of D Lin was a comparative study on the malignant and non‐malignant PC in China. The heterogeneity in PC versus control subgroup significantly decreased to 27%. Five studies on miR‐375 were divided into three subgroups: PC versus control, serum, and urine. The heterogeneities in PC versus control and serum subgroups were significantly reduced to 23% and 0%, respectively. The analyses of the above‐mentioned subgroups showed that the expression of miR‐375 in the urine samples were widely different, and also deviated from the expression profiles of tissues and plasma samples.

In addition to the above mentioned miRNAs expression data, there were also significant heterogeneities in the studies on seven miRNAs (Figure [4](#jcb26445-fig-0004){ref-type="fig"}). Among them, studies on miR‐10b, miR‐18a, miR‐30c, and miR‐206, research data from Beatriz A. Walter[23](#jcb26445-bib-0023){ref-type="ref"} deviated significantly from other research data. The heterogeneity decreased significantly when we rejected the deviant data. Moreover, in several studies on miR‐139‐5p and miR‐182, Cheng Pang[24](#jcb26445-bib-0024){ref-type="ref"} and Fan Feng[21](#jcb26445-bib-0021){ref-type="ref"} detected miRNAs expression profiles in whole blood and urine, respectively, which could explain the causes of heterogeneity. Finally, in three studies about miR‐146 a, Bin Xu[25](#jcb26445-bib-0025){ref-type="ref"} collected ADPC and AIPC patients\' samples in China, which were obviously different from the other two studies by Katia R. M. Leite[26](#jcb26445-bib-0026){ref-type="ref"}, [27](#jcb26445-bib-0027){ref-type="ref"} in Brazil.

Studies on 14 miRNAs (miR‐31, miR‐124, miR‐125a, miR‐133a/b, miR‐154, miR‐181a/b/c, miR‐203, miR‐210, miR‐218, miR‐378, and miR‐548c) had separately 2‐3 studies with significant heterogeneity (Figure [5](#jcb26445-fig-0005){ref-type="fig"}). These studies only opened the gateway for the diagnosis and prognosis potential of 14 miRNAs, more researches are needed to confirm their application value in clinic.

3.4. miRNA expression and recurrence‐free survival {#jcb26445-sec-0012}
--------------------------------------------------

Biochemical recurrence (BCR) was considered as the first key point to estimate treatment success after RP. BCR can predate the development of metastases and other signs of clinical progression, or ultimately death. Recently, a lot of studies attempted to find miRNAs to be potential predictors for patients with biochemical failure. We summarized previous data in the meta‐analysis, miR‐30c, miR‐129, miR‐145, and let‐7c were found to have the same trend to predict BCR in eight articles (Figure [6](#jcb26445-fig-0006){ref-type="fig"}B‐E). While the relationship of miR‐21 and BCR were studied in four articles with significant heterogeneity (Figure [6](#jcb26445-fig-0006){ref-type="fig"}A). After reviewing the four full texts, we found that Ernest K Amankwah[28](#jcb26445-bib-0028){ref-type="ref"} examined the effect of the interaction between obesity and miR‐21 expression on PC recurrence. Obese patients were included in the study. Removing the data from Ernest K Amankwah, miR‐21 could distinguish biochemical failure patients from non‐recurrence (Figure [6](#jcb26445-fig-0006){ref-type="fig"}A).

In remaining 20 articles, we found prostate tumors with high levels of miR‐10b, miR‐100, miR‐106b, miR‐133b, miR‐150, miR‐191, miR‐301a, miR‐449b, miR‐663, or miR‐1207‐3p have significant decrease in RFS, while low levels of miR‐23a/b, miR‐27b, miR‐34b, miR‐224, miR‐466, miR‐709, and let‐7b were significantly correlated with poorer RFS (Table [3](#jcb26445-tbl-0003){ref-type="table-wrap"}). Five miRNAs (miR‐205, miR‐221, miR‐222, miR‐383, and miR‐3622b) were detected no correlation between the expression levels and tumor progression (*P* \> 0.05).

3.5. miRNA expression and overall survival {#jcb26445-sec-0013}
------------------------------------------

A total of 11 records comprised OS analysis involving 15 miRNAs (Table [4](#jcb26445-tbl-0004){ref-type="table-wrap"} and Figure [6](#jcb26445-fig-0006){ref-type="fig"}F). Among three articles on miR‐375, significant heterogeneity was observed (*P* = 0.03, *I* ^2 ^= 70%). After reviewing three full texts, we found plasma samples were used in the studies of Hui‐ming Lin[29](#jcb26445-bib-0029){ref-type="ref"} and Xiaoyi Huang,[30](#jcb26445-bib-0030){ref-type="ref"} while serum samples were used in the study of Sven Wach.[31](#jcb26445-bib-0031){ref-type="ref"} Removing the data from Sven Wach, the heterogeneity was markedly decreased (*P* = 0.67, *I* ^2^ = 0%) (Figure [6](#jcb26445-fig-0006){ref-type="fig"}F). Hence, a fixed model was applied to calculate a pooled RR and 95%CI, and we found that patients with high miR‐375 expression had significantly poorer OS compared to low miR‐375 expression (RR = 2.93, 95%CI, 1.96‐4.40) (Figure [6](#jcb26445-fig-0006){ref-type="fig"}F).

In the other eight studies involving 14 miRNAs (Table [4](#jcb26445-tbl-0004){ref-type="table-wrap"}), eight miRNAs (miR‐132, miR‐150, miR‐200a/b/c, miR‐429, miR‐708, and miR‐1290) were showed that increased expression predicted significantly worse OS, and low expression of four miRNAs (miR‐23a, miR‐23b, miR‐221, and miR‐224) were associated with poorer OS. Moreover, in the analyses on miR‐205 and miR‐1207‐3p, no statistically significant results were observed. It was worth noting that miR‐200a, miR‐200b, miR‐200c, and miR‐429 were the members of the same family, their change trends were consistent in different studies, and all of them were associated with poorer OS.

4. DISCUSSION {#jcb26445-sec-0014}
=============

The major challenges for PC clinical management were its accurate diagnosis and dynamic monitoring after RP, chemotherapy or radiotherapy, etc. Although PSA routinely screening improved the ratio of early detection, its levels was poorly associated with tumor aggressiveness, and had a little help to predict PC patients\' prognosis. Moreover, biopsies were not only invasive but also not conclusive, for example, sampling errors could lead to missed diagnosis and wrong therapies in clinic, especially in the cases with multifocal PC.

Recently, miRNAs had been found to be closely associated with a variety of tumors by regulating their target genes to affect carcinogenesis and progression. And a number of researches showed a significant correlation between the expression levels of miRNAs and the diagnosis and prognosis of PC. These study data would be helpful miRNAs as biomarkers to be transfer into the clinical application for diagnosis and prognosis of PC. Moreover, Compared to mRNAs, clinical samples containing miRNAs are more likely to be collected and detested because miRNAs are stable not to be easily degraded. The expression profiles of miRNAs are special in various cancer or normal tissues. And they can be accurately quantified by microarray, qRT‐PCR, and RNA sequencing in not only frozen or fresh or formalin‐fixed paraffin‐embedded tissues, but also serum or plasma samples, even in urine or saliva samples. However, these results on the clinical value of miRNAs were inconsistent and even contradictory due to the clinical complexity of PC. Therefore, it is necessary to conduct stratified and systematic analyses to confirm their expression pattern and application scope.

By meta‐analyses of included studies, we successfully come to some valuable conclusions for future applications in clinic. The most studied miRNA was miR‐21, with 11 articles providing the data of its expression level in clinical PC samples. Secondly, the expression profile data of miR‐221 and miR‐205 were clearly reported in seven and six studies, respectively. And the expression levels of 7 miRNAs (miR‐25, miR‐32, miR‐100, miR‐125b, miR‐141, miR‐222, miR‐375) were reported in five literatures. In addition, the most obviously increased miRNAs were the members of the miR‐200 family: miR‐200a and miR‐200b, their HR and 95%CI were 5.17 (3.22‐7.13) and 4.08 (2.91‐5.24), respectively. The most significantly decreased miRNA was miR‐199a, its pooled HR and 95%CI was −4.23 (−16.22‐7.76).

In order to remove the interference of genetic backgrounds due to patients\' ethnic groups, the included studies were classified into China subgroup and Brazil subgroup, etc. We found increased miR‐21 expression could distinguish PC patients from normal controls, and could predict a significantly poor RFS. The expression of miR‐100 in the Brazilian population was significantly reduced, and HR and 95%CI was −77.57 (−110.47, −44.67). The different expression levels and predictive values of miRNAs may be explained by the differences of hereditary backgrounds and environmental exposures.

Second, we conducted subgroup analyses depending on the pathological types of PC to classify the enrolled studies into subgroups of cancer categories: normal controls/BPH, primary/local PC, metastatic PC, high‐risk PC, and recurrence PC/non‐recurrence PC subgroups, etc. In the comparisons of the expression profiles of miRNAs in primary/local PC versus metastatic PC subgroups, we found that miR‐21 and miR‐32 were up‐regulated in metastatic PC tissues, while miR‐25, miR‐143, miR‐145, miR‐191, and let‐7c were down‐regulated. In subgroup analyses of PC versus control, we found that miR‐141, miR‐200c, and miR‐375 were increased, while miR‐30 c, miR‐143, miR‐145, miR‐191, miR‐221, miR‐222, and let‐7c were reduced. Among them, low expression of three miRNAs (miR‐30c, miR‐45, and let‐7c) predicted worse RFS, the HR 95%CI were 0.32 (0.15‐0.66), 3.86 (1.85‐8.03), and 3.14 (1.49‐6.60), respectively. In addition, the expression model of miR‐15a and miR‐16 was special, both of them were lower expressed in PC tissues than that in normal controls, and their expression levels were increased again when PC progressed to malignant metastatic stages.

Finally, we performed subgroup analyses to clarify the diagnostic values of miRNAs based on the data of serum/plasma and urine samples, etc. We found that high‐expression of miR‐375 was significantly associated with a worse OS (HR = 2.93, 95%CI 1.96‐4.40) in serum/plasma subgroup, and its high‐expression was also shown in tissue subgroup (HR = 7.41, 95%CI 6.49‐8.33) and urine subgroup (HR = 1799.29, 95%CI 1796.45‐1802.13). In addition, we processed subgroup analyses of the expression levels of other five miRNAs in serum or urine samples. Among them, the members of miR‐200 family: miR‐141 and miR‐200c were up‐regulated, while the expression levels of miR‐221 and miR‐221 were decreased. The expression of miR‐100 was increased in the urine samples, which was contrary to its expression in patients\' tissues. Although the detection of miRNAs in tissues was widely accepted by researchers and doctors to diagnose and predict PC progression, the detection in serum or urine samples was more convenient and uninjurious, which could dynamically monitor the therapeutic effects and patients\' prognosis at any time point of the lifetime of PC patients.

The meta‐analysis has some merits. First, we strictly followed the literature inclusion criteria and the quality of enrolled literatures was satisfactory. Second, we conducted subgroup analyses to effectively minimize the influence of heterogeneity among the enrolled studies, and to further explore the scope of application for miRNAs as a prognostic biomarker of malignant tumors. All of these have increased the statistical power of the meta‐analysis. But there are also many shortcomings in the meta‐analysis. First, only a few articles are eligible for a kind of miRNA leading to the relative shortage in subgroup analyses. Secondly, after data integration and subgroup analyses, some miRNAs data still lack statistical significance, such as miR‐15a (*P* = 0.45), miR‐16 (*P* = 0.69), miR‐21 (*P* = 0.49), miR‐25 (*P* = 0.83), miR‐191 (*P* = 0.49), and miR‐200c (*P* = 0.63), etc. Besides, no study is carried out in Africa, which blocks the integrated investigation of the association between miRNAs expression and PC diagnosis and prognosis. Finally, because of the lack of unified cut‐off value of miRNAs expression in different researches, which would reduce the potency of miRNAs as predictive biomarkers. Therefore, the application value of miRNAs as prognostic factors for PC is still controversial, requiring more researches to verify.

5. CONCLUSIONS {#jcb26445-sec-0015}
==============

The potential use of miRNAs as diagnosis and prognosis factors for PC in the clinic was based on a growing body of investigations in the last decades. Currently, ongoing researches were still controversial that delayed the transformation from bench to bedside. Nevertheless, the potential value of miRNAs used in clinical practice had been generally accepted, which represented not only promising biomarkers for PC but also candidated therapeutic targets. Besides, detecting the expression levels of miRNAs in serum or plasma or urine samples was more exciting than detecting miRNAs in tissues, because of low cost, rapid test, and noninvasion, etc. However, in this meta‐analysis, we found that the expression profiles of miRNAs in the blood samples were different from that of the tissues, and the deviation in the urine samples was more obvious.

Due to the lack of relevant data, further studies in larger sample sizes are needed to conduct more precise stratification between miRNAs expression levels and different progression stages of PC. We will also continue to evaluate and report the clinical value of miRNAs detection when larger studies further verify the validity of miRNAs. The guidelines on study design and sample collection still need to be further improved, in particular, the detecting platforms should be clearly defined. Taken together, the meta‐analysis underline that the use of miRNAs as biomarkers for diagnosis and prediction of PC is promising, though not yet a reality in clinical practice.
